Biogen currently co-markets Sage’s postpartum depression (PPD) drug Zurzuvae (zuranolone). Despite rejecting the offer, Sage’s board has stated it will consider “strategic alternatives” to ...

Sage’s board wrote in late January that the offer “significantly undervalues” the company, which is currently working with Biogen towards commercializing ZURZUVAE, the first and only oral ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Zurzuvae (part of the Sage collaboration) is also launching and seeing solid demand in postpartum depression. Biogen has an Ionis-partnered pipeline to follow Spinraza in areas including Parkinson ...

Zurzuvae (zuranolone) was launched for postpartum depression in December 2023. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses ...

The silver lining for Biogen, however, is that sales from four recent launches—Skyclarys, Leqembi, Zurzuvae and Qalsody— “more than offset the decline in our multiple sclerosis product ...

Biogen expects 2025 non-GAAP EPS of $15.25-$ ... driven by SKYCLARYS and ZURZUVAE. LEQEMBI global in-market sales reached $87 million, growing 30% sequentially, with U.S. sales accounting for ...

Biogen posted fourth-quarter revenue and profit ... that can impair walking and coordination in children as young as 5. Zurzuvae, the first pill for postpartum depression, generated fourth ...

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported quarter, the company beat earnings expectations by 8.22%. The Zacks Consensus ...